Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Professor Paul Workman Joins Nuevolution as Scientific Advisor

Published: Friday, July 11, 2014
Last Updated: Thursday, July 10, 2014
Bookmark and Share
Professor Workman brings a vast knowledge and expertise within the oncology field.

Nuevolution has announced that Professor Paul Workman has joined as Scientific Advisor. Paul brings a vast knowledge and expertise within the oncology field to Nuevolution as well as profound understanding of bridging research discoveries with commercial value.

Professor Workman is an exceptionally experienced research leader, having achieved a high level of success in academia, biotech companies and the pharmaceutical industry. He is a Biochemist and Cancer Pharmacologist by training and he has worked at a number of academic institutions including Cambridge University, UK, Stanford University, California and the University of Glasgow, UK before moving to AstraZeneca, Alderley Park, UK as Head of the Cancer Bioscience Section in 1993.

In 1997, Paul joined The Institute of Cancer Research (ICR), London to build the Cancer Research UK Cancer Therapeutics Unit (CTU) and also co-founded two successful biotech companies, Piramed Pharma and Chroma Therapeutics. As well as being the Director of the ICR’s CTU and Harrap Professor of Pharmacology and Therapeutics, Paul was recently appointed Interim Chief Executive of ICR, having been Deputy CEO for the last 3 years.

Paul has received many scientific achievement awards including the American Association of Cancer Research Team Science Award (Team Leader) in 2012 and Cancer Research UK Translational Cancer Research Prize (Joint Leader of HSP90 Team) in 2013.

In addition, he has received both the Sosnovsky Award in Cancer Therapy (2010) and the World Entrepreneur of the Year Award (2012) from the Royal Society of Chemistry and earlier this year received the international Raymond Bourgine Award for excellence in cancer research.

“We are happy to further expand our collaboration with Paul and to have him join our expert advisory panel. Paul and his team at ICR have had a truly remarkable success rate and an outstanding track record in bringing compounds to the clinic” said Thomas Franch, CSO of Nuevolution. “We are certain that Paul’s expertise will help accelerate our oncology projects further to meet our ambitions of providing novel compounds for cancer treatment.”

Professor Workman said: “I am delighted to join Nuevolution’s advisors and am impressed by their proprietary Chemetics® technologies that provide an unprecedented capability for the identification of drug leads and a strong potential to address major unmet medical needs”.

Nuevolution is dedicated to the identification and progression of novel compounds addressing unmet medical needs with a main disease focus on Inflammation and Oncology.

The company currently has efforts on more than 30 disease targets at various discovery stages in its pipeline or in collaboration with several industrial, institutional and academic partners.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nuevolution A/S Appoints Professor Mark C. Genovese as Advisor
Appointment to support the companies’ pre-clinical and clinical efforts in inflammatory diseases.
Saturday, November 21, 2015
Nuevolution Announces Drug Discovery Collaboration with J&J Innovation
Company will apply its drug discovery platform Chemetics® to discover and advance drug candidates.
Tuesday, October 27, 2015
Dr. Jeanette Wood Joins Nuevolution
Jeanette joins the Company as director and senior scientific advisor to the board of directors.
Tuesday, September 22, 2015
Nuevolution Appoints Henrik Simonsen
Former Director of Life Science Corporate Finance at SEB joins as its Chief Financial Officer.
Thursday, September 17, 2015
Brian Zambrowicz Joins Nuevolution as Director and Senior Scientific Advisor
Company also announces other Board of Directors.
Thursday, May 22, 2014
Nuevolution, Merck License Agreement
Agreement for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.
Friday, February 21, 2014
Nuevolution Announces Technology Licensing Agreement
Agreement with Novartis for use of Nuevolution’s Chemetics® technology.
Friday, January 10, 2014
Nuevolution Appoints Ton Berkien as Chief Business Officer
Ton Berkien will join the company on January 1, 2014.
Tuesday, December 10, 2013
Nuevolution Announces Formation of Strong Scientific Advisory Panel
Company teams with scientific advisors to assist the progression of its internal drug discovery programs.
Thursday, March 14, 2013
Nuevolution A/S Raises € 11 Million in New Financing Round
New financing round will enable Nuevolution to transform its current business model.
Friday, June 22, 2012
Nuevolution Announces Collaboration in Drug Discovery with Boehringer Ingelheim
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Wednesday, September 21, 2011
Nuevolution Enters Lead Discovery Collaboration in the Field of Epigenetic Disorders
A consortium has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.
Thursday, October 07, 2010
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!